

Chief Technology Officer

Presymptom Health is rapidly growing and anticipates closing an advanced seed round by early Q1 2021. The company now seeks a Chief Technology Officer to take ownership of all research and development activities.

This role will play a vital part in the development of a prognostic technology with the potential to impact over 49M sepsis patients annually, together with a broader portfolio targeted at broader infectious disease and acute care management.

Presymptom will operate virtually, via a small core team and hot-desk model, to develop its genomic and proteomic reagent kits and interpretive algorithms primarily on 3rd party molecular and proteomic platforms.

The successful candidate will lead the development of Presymptom's clinical trial program and technology portfolio, and support the CEO with oversight of vendors/partners to ensure transition to an ISO13485-compliant development process.

Requirements

The ideal candidate will have an appropriate mix of the following experience:

- Bachelor of Science/masters degree in molecular biology, biochemistry or a related discipline.
- A minimum of 15 years IVD industry R&D leadership experience, including a track record of successful medical product development.
- Significant hands-on technical experience in technologies such as molecular biology, immunoassay, and lateral flow.
- Knowledge/experience of AI-driven innovation, ideally including both clinical and -omic parameters.
- Development experience within an ISO13485-compliant environment; familiarity with FDA CFR part 820 requirements.

continued...

- (Ideally) Knowledge of development of regulated medical software and AI and other applicable international standards, including ISO/IEC 27001 and ISO/IEC 27701.
- (Ideally), experience implementing quality management systems.
- Knowledge of Good Laboratory Practice.
- Strong communication skills; able to present compelling vision to internal and external stakeholders.
- (Ideally) project management skillset, including state of the art approaches (PRINCE, etc).

About

Presymptom Health was established by the UK Ministry of Defence's technology transfer team at Ploughshare Innovations to commercialise a set of unique early sepsis and infection disease diagnostic assets developed by the Defence Science & Technologies Laboratory (Dstl). These assets, comprising a 72,000-sample biobank, clinical outcomes database and several predictive diagnostic signatures, arose from a unique 10-year £16M surgical inpatient study which recruited 4,400 patients before they developed infections. The study is the subject of a recent submission to a leading clinical journal.

- **Email:** info@presymptom.com
- **LinkedIn:** www.linkedin.com/company/presymptom
- **Twitter:** [@PresymptomH](https://twitter.com/PresymptomH)

Applications / Further Information

Presymptom Health is interested in engaging with interested parties ahead of completion of its advanced seed round that is anticipated in January 2021. Geographic location is flexible.

For further details, or to express an interest in this exciting role, please contact Iain Miller (CEO): iain.miller@presymptom.com

